Intravenous administration of Bone marrow mononuclear cells alleviates hearing loss after transient cochlear ischemia through paracrine effects

Taro Takagi, Tadashi Yoshida, Masahiro Okada, Ryuji Hata, Naohito Hato, Kiyofumi Gyo, Nobuhiro Hakuba

Research output: Contribution to journalArticle

Abstract

Bone marrow mononuclear cells (BMMCs) are known to enhance recovery from ischemic insults by secreting angiogenic factors and inducing the expression of angiogenic factors from host tissues. Therefore, the transplantation of BMMCs is considered a potential approach to promoting the repair of ischemic damaged organs. Here, we investigated the influence of BMMCs on progressive hair cell degeneration after transient cochlear ischemia in gerbils. Transient cochlear ischemia was produced by extracranial occlusion of the bilateral vertebral arteries immediately before their entry into the transverse foramen of the cervical vertebra. An intravenous injection of BMMCs prevented ischemia-induced hair cell degeneration and ameliorated hearing impairment. A tracking study showed that BMMCs injected into the femoral vein were limited in the spiral artery of the cochlea, suggesting that, although transplanted BMMCs were retained within the spiral ganglion area of the cochlea, they were neither transdifferentiated into cochlear cells nor fused with the injured hair cells and supporting cells in the organ of Corti to restore their functions. We also showed that the protein level of neurotrophin-3 and glial cell line-derived neurotrophic factor in the organ of Corti was upregulated after treatment with BMMCs. These results suggested that BMMCs have therapeutic potential possibly through paracrine effects. Thus, we propose the use of BMMCs as a potential new therapeutic strategy for hearing loss.

Original languageEnglish
Pages (from-to)807-813
Number of pages7
JournalNeuroReport
Volume25
Issue number11
DOIs
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Cochlea
Hearing Loss
Bone Marrow Cells
Intravenous Administration
Ischemia
Organ of Corti
Angiogenesis Inducing Agents
Spiral Ganglion
Neurotrophin 3
Glial Cell Line-Derived Neurotrophic Factor
Cervical Vertebrae
Femoral Vein
Vertebral Artery
Gerbillinae
Bone Marrow Transplantation
Intravenous Injections
Therapeutics
Arteries

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Takagi, Taro ; Yoshida, Tadashi ; Okada, Masahiro ; Hata, Ryuji ; Hato, Naohito ; Gyo, Kiyofumi ; Hakuba, Nobuhiro. / Intravenous administration of Bone marrow mononuclear cells alleviates hearing loss after transient cochlear ischemia through paracrine effects. In: NeuroReport. 2014 ; Vol. 25, No. 11. pp. 807-813.
@article{ac86892d9cfc45159f59d95911c0e404,
title = "Intravenous administration of Bone marrow mononuclear cells alleviates hearing loss after transient cochlear ischemia through paracrine effects",
abstract = "Bone marrow mononuclear cells (BMMCs) are known to enhance recovery from ischemic insults by secreting angiogenic factors and inducing the expression of angiogenic factors from host tissues. Therefore, the transplantation of BMMCs is considered a potential approach to promoting the repair of ischemic damaged organs. Here, we investigated the influence of BMMCs on progressive hair cell degeneration after transient cochlear ischemia in gerbils. Transient cochlear ischemia was produced by extracranial occlusion of the bilateral vertebral arteries immediately before their entry into the transverse foramen of the cervical vertebra. An intravenous injection of BMMCs prevented ischemia-induced hair cell degeneration and ameliorated hearing impairment. A tracking study showed that BMMCs injected into the femoral vein were limited in the spiral artery of the cochlea, suggesting that, although transplanted BMMCs were retained within the spiral ganglion area of the cochlea, they were neither transdifferentiated into cochlear cells nor fused with the injured hair cells and supporting cells in the organ of Corti to restore their functions. We also showed that the protein level of neurotrophin-3 and glial cell line-derived neurotrophic factor in the organ of Corti was upregulated after treatment with BMMCs. These results suggested that BMMCs have therapeutic potential possibly through paracrine effects. Thus, we propose the use of BMMCs as a potential new therapeutic strategy for hearing loss.",
author = "Taro Takagi and Tadashi Yoshida and Masahiro Okada and Ryuji Hata and Naohito Hato and Kiyofumi Gyo and Nobuhiro Hakuba",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/WNR.0000000000000167",
language = "English",
volume = "25",
pages = "807--813",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

Intravenous administration of Bone marrow mononuclear cells alleviates hearing loss after transient cochlear ischemia through paracrine effects. / Takagi, Taro; Yoshida, Tadashi; Okada, Masahiro; Hata, Ryuji; Hato, Naohito; Gyo, Kiyofumi; Hakuba, Nobuhiro.

In: NeuroReport, Vol. 25, No. 11, 01.01.2014, p. 807-813.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravenous administration of Bone marrow mononuclear cells alleviates hearing loss after transient cochlear ischemia through paracrine effects

AU - Takagi, Taro

AU - Yoshida, Tadashi

AU - Okada, Masahiro

AU - Hata, Ryuji

AU - Hato, Naohito

AU - Gyo, Kiyofumi

AU - Hakuba, Nobuhiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Bone marrow mononuclear cells (BMMCs) are known to enhance recovery from ischemic insults by secreting angiogenic factors and inducing the expression of angiogenic factors from host tissues. Therefore, the transplantation of BMMCs is considered a potential approach to promoting the repair of ischemic damaged organs. Here, we investigated the influence of BMMCs on progressive hair cell degeneration after transient cochlear ischemia in gerbils. Transient cochlear ischemia was produced by extracranial occlusion of the bilateral vertebral arteries immediately before their entry into the transverse foramen of the cervical vertebra. An intravenous injection of BMMCs prevented ischemia-induced hair cell degeneration and ameliorated hearing impairment. A tracking study showed that BMMCs injected into the femoral vein were limited in the spiral artery of the cochlea, suggesting that, although transplanted BMMCs were retained within the spiral ganglion area of the cochlea, they were neither transdifferentiated into cochlear cells nor fused with the injured hair cells and supporting cells in the organ of Corti to restore their functions. We also showed that the protein level of neurotrophin-3 and glial cell line-derived neurotrophic factor in the organ of Corti was upregulated after treatment with BMMCs. These results suggested that BMMCs have therapeutic potential possibly through paracrine effects. Thus, we propose the use of BMMCs as a potential new therapeutic strategy for hearing loss.

AB - Bone marrow mononuclear cells (BMMCs) are known to enhance recovery from ischemic insults by secreting angiogenic factors and inducing the expression of angiogenic factors from host tissues. Therefore, the transplantation of BMMCs is considered a potential approach to promoting the repair of ischemic damaged organs. Here, we investigated the influence of BMMCs on progressive hair cell degeneration after transient cochlear ischemia in gerbils. Transient cochlear ischemia was produced by extracranial occlusion of the bilateral vertebral arteries immediately before their entry into the transverse foramen of the cervical vertebra. An intravenous injection of BMMCs prevented ischemia-induced hair cell degeneration and ameliorated hearing impairment. A tracking study showed that BMMCs injected into the femoral vein were limited in the spiral artery of the cochlea, suggesting that, although transplanted BMMCs were retained within the spiral ganglion area of the cochlea, they were neither transdifferentiated into cochlear cells nor fused with the injured hair cells and supporting cells in the organ of Corti to restore their functions. We also showed that the protein level of neurotrophin-3 and glial cell line-derived neurotrophic factor in the organ of Corti was upregulated after treatment with BMMCs. These results suggested that BMMCs have therapeutic potential possibly through paracrine effects. Thus, we propose the use of BMMCs as a potential new therapeutic strategy for hearing loss.

UR - http://www.scopus.com/inward/record.url?scp=84926103878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926103878&partnerID=8YFLogxK

U2 - 10.1097/WNR.0000000000000167

DO - 10.1097/WNR.0000000000000167

M3 - Article

AN - SCOPUS:84926103878

VL - 25

SP - 807

EP - 813

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 11

ER -